CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.
Insider & Institutional Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares CRISPR Therapeutics and Vaxcyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -118.13% | -12.15% | -10.35% |
| Vaxcyte | N/A | -23.53% | -22.20% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $200.00 million | 17.51 | -$153.61 million | ($2.83) | -14.49 |
| Vaxcyte | N/A | N/A | -$402.27 million | ($4.60) | -18.45 |
CRISPR Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CRISPR Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for CRISPR Therapeutics and Vaxcyte, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 8 | 9 | 0 | 2.44 |
| Vaxcyte | 0 | 0 | 8 | 0 | 3.00 |
CRISPR Therapeutics currently has a consensus price target of $77.93, indicating a potential upside of 89.99%. Vaxcyte has a consensus price target of $145.71, indicating a potential upside of 71.71%. Given CRISPR Therapeutics’ higher probable upside, research analysts clearly believe CRISPR Therapeutics is more favorable than Vaxcyte.
Summary
CRISPR Therapeutics beats Vaxcyte on 10 of the 13 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About Vaxcyte
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
